Riskpilot← Back to searchSign inGet full accessProvisus Pharma AB
ABActiveOrg 5593853558Hyllegatan 33Wholesale of other food · NACE 4638Est. 20220 employees
Revenue 2025
SEK 279K
+61% vs 2024
EBITDA margin
26.5%
+189% vs 2024
Equity ratio
39.6%
Financial strength
Net profit 2025
SEK 74K
+189% vs 2024
| Revenue | SEK 279K | +61% |
| EBITDA | SEK 74K | +189% |
| Net profit | SEK 74K | +189% |
| Total assets | SEK 313K | +422% |
| Equity | SEK 124K | +148% |
| Employees | 0 | — |
Legal name
Provisus Pharma AB
Org number
5593853558
Legal form
Aktiebolag
NACE code
4638 · Wholesale of other food
Founded
16 juni 2022
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolagets verksamhet är sälja läkemedel och kosttillskott, köp och försäljning av värdepapper, äga och förvalta fast och lös egendom samt därmed förenlig verksamhet.
Address
Hyllegatan 33
Email
agl@rexis.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 119 | 173 | 279 |
| Staff expenses | — | — | — |
| EBITDA | −52 | −83 | 74 |
| Depreciation & amort. | — | −0 | −0 |
| EBIT | −52 | −83 | 74 |
| Net financials | 0 | — | — |
| Profit before tax | −51 | −83 | 74 |
| Tax | — | −0 | −0 |
| Net profit | −51 | −83 | 74 |
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 287 | 60 | 313 |
| Equity | 74 | 50 | 124 |
| Long-term debt | — | 0 | 0 |
| Short-term debt | 214 | 10 | 189 |
| Total debt | 214 | 10 | 189 |
EBITDA margin
26.5%
This company
15.8%
Market median
+68% vs market
20232025
Equity ratio
39.6%
This company
38.2%
Market median
+4% vs market
20232025
Return on equity
59.7%
This company
18.4%
Market median
+224% vs market
20232025
Net profit margin
26.5%
This company
8.1%
Market median
+227% vs market
20232025
Asset turnover
0.89×
This company
1.12×
Market median
+21% vs market
20232025
Debt / equity
1.52×
This company
0.62×
Market median
-145% vs market
20232025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-06-16 – 2023-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MP Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2025 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Rexis AB | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rexis AB
Provisus Pharma AB Board members of Provisus Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Peter Karlsson | Chief Executive Officer | 0 companies |
| Beate Amalie Lejre Lejre | Deputy Board Member | 0 companies |
| Anna-Carin Agneta Åberg | Deputy Board Member | 0 companies |
| Johan Anders Lejre | Chairman | 0 companies |
| William Lejre | Deputy Board Member | 0 companies |
| Therese Lejre | Board of Directors | 0 companies |